Successful chemotherapy for recurrent malignant oligodendroglioma.
Eight consecutive patients with recurrent malignant oligodendroglioma were treated with systemic chemotherapy. Six patients received a combination of procarbazine, lomustine (CCNU), and vincristine; 1 received carmustine (BCNU), and 1 diaziquone. All responded by clinical and computed tomographic scan criteria. One patient had a complete response for 78 weeks, and 7 patients had unequivocal partial responses lasting 30+ to 68+ weeks. Two partial responders had complete control of systemic metastases. Malignant oligodendroglioma is a uniquely chemosensitive glial tumor.
Cairncross
J G
JG
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
Macdonald
D R
DR
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D016227:Benzoquinones; D001932:Brain Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000188:drug therapy*; D011344:Procarbazine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine; C029108:diaziquone; D002330:Carmustine